Archive · 29 Jul 2026
India's SHetA2 Pill: Hope for HPV-Related Cervical Precancer
India has developed a new pill called SHetA2 that might help treat precancerous changes in the cervix caused by HPV.
Unlike vaccines that prevent HPV, this pill is for women who already have these changes.
It's still being tested and won't be available for a few years.
Experts say it's important not to get too excited yet because the pill needs more testing to make sure it's safe and works well.
For now, women should still get vaccinated and have regular screenings to prevent cervical cancer.
SHetA2 is an investigational oral drug targeting HPV-related precancerous cervical lesions.
Developed by ICMR and licensed to Emcure Pharmaceuticals.
Designed to treat women with existing precancerous changes, not prevent HPV infection.
Still several years away from routine clinical use due to ongoing trials.
Potential benefits include a non-surgical treatment option with tissue-preserving properties.
- Who
- Developed by ICMR and licensed to Emcure Pharmaceuticals
- What
- An investigational oral drug targeting HPV-related precancerous cervical lesions
- When
- Still several years away from routine clinical use
- Where
- India
- Why
- To offer a non-surgical treatment option for women with cervical intraepithelial neoplasia (CIN)
Optimistic View
Cautious View
Immediate Availability
Optimistic View
The pill is a breakthrough and will be available soon.
Cautious View
The pill is still years away from being available to the public.
Effectiveness
Optimistic View
SHetA2 will effectively treat precancerous lesions without surgery.
Cautious View
The pill's effectiveness is still under investigation and not guaranteed.
- Developer
- Indian Council of Medical Research (ICMR) and Emcure Pharmaceuticals
- Target
- HPV-related precancerous cervical lesions
- Current Status
- Under clinical development
- Potential Benefits
- Non-surgical treatment option
- Challenges
- Pricing, manufacturing, and distribution